<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0002">
 <label>Table 2</label>
 <caption>
  <p>The potential vaccine candidates for COVID-19 
   <xref rid="bib0135" ref-type="bibr">[135]</xref>, 
   <xref rid="bib0136" ref-type="bibr">[136]</xref>, 
   <xref rid="bib0137" ref-type="bibr">[137]</xref>, 
   <xref rid="bib0138" ref-type="bibr">[138]</xref>, 
   <xref rid="bib0139" ref-type="bibr">[139]</xref>, 
   <xref rid="bib0140" ref-type="bibr">[140]</xref>, 
   <xref rid="bib0141" ref-type="bibr">[141]</xref>, 
   <xref rid="bib0142" ref-type="bibr">[142]</xref>, 
   <xref rid="bib0143" ref-type="bibr">[143]</xref>, 
   <xref rid="bib0144" ref-type="bibr">[144]</xref>, 
   <xref rid="bib0145" ref-type="bibr">[145]</xref>.
  </p>
 </caption>
 <alt-text id="alt0010">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" valign="top"/>
    <th valign="top">Candidate</th>
    <th valign="top">Vaccine characteristics</th>
    <th valign="top">Lead developer/sponsor</th>
    <th valign="top">Current status</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="8" align="left" valign="top">Clinical-phase</td>
    <td valign="top">INO-4800</td>
    <td valign="top">DNA plasmid encoding S protein delivered via electroporation</td>
    <td valign="top">Inovio Pharmaceuticals</td>
    <td valign="top">Phase I (NCT04336410)</td>
   </tr>
   <tr>
    <td valign="top">mRNA-1273</td>
    <td valign="top">LNP-encapsulated mRNA vaccine encoding S protein</td>
    <td valign="top">Moderna</td>
    <td valign="top">Phase I (NCT04283461)</td>
   </tr>
   <tr>
    <td valign="top">LV-SMENP-DC</td>
    <td valign="top">DCs modified with lentiviral vector expressing synthetic minigene based upon domains of selected viral proteins;</td>
    <td valign="top">Shenzhen Geno-Immune Medical Institute</td>
    <td valign="top">Phase I (NCT04276896)</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Recombinant novel coronavirus (2019-CoV) vaccine (adenoviral vector)</td>
    <td valign="top">Institute of Military Medicine under the Academy of Military Sciences of the People's Liberation Army of China</td>
    <td valign="top">Phase II (ChiCTR2000030906)</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Inactivated vaccine</td>
    <td valign="top">Beijing Institute of Biological Products/Wuhan Institute of Biological Products</td>
    <td valign="top">Phase I
     <break/>(ChiCTR2000031809)
    </td>
   </tr>
   <tr>
    <td valign="top">ChAdOx1</td>
    <td valign="top">Attenuated adenovirus capable of producing the S protein of SARS-CoV-2</td>
    <td valign="top">University of Oxford</td>
    <td valign="top">Phase I/II
     <break/>(NCT04324606)
    </td>
   </tr>
   <tr>
    <td valign="top">Ad5-nCoV</td>
    <td valign="top">Adenovirus type 5 vector that expresses S protein</td>
    <td valign="top">CanSino Biologicals</td>
    <td valign="top">Phase I (NCT04313127)</td>
   </tr>
   <tr>
    <td valign="top">Pathogen-specific aAPC</td>
    <td valign="top">aAPCs modified with lentiviral vector expressing synthetic minigene based upon domains of selected viral proteins</td>
    <td valign="top">Shenzhen Geno-Immune Medical Institute</td>
    <td valign="top">Phase I (NCT04299724)</td>
   </tr>
   <tr>
    <td rowspan="10" align="left" valign="top">Experimental-phase</td>
    <td valign="top">/</td>
    <td valign="top">Single-dose intranasal replication-defective adenovirus vector vaccine incorporating the SARS-CoV-2 S protein</td>
    <td valign="top">Altimmune</td>
    <td valign="top">Phase 1 trial planned for mid-August.</td>
   </tr>
   <tr>
    <td valign="top">BNT162</td>
    <td valign="top">mRNA vaccine expressing codon-optimized undisclosed SARS-CoV-2 proteins</td>
    <td valign="top">BioNTech</td>
    <td valign="top">Clinical testing to begin late April</td>
   </tr>
   <tr>
    <td valign="top">STARR</td>
    <td valign="top">Self-transcribing and replicating RNA vaccine expressing undisclosed epitopes</td>
    <td valign="top">Arcturus</td>
    <td valign="top">Manufacturing stage</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Protamine-complexed mRNA-based vaccine expressing undisclosed SARS-CoV-2 protein(s)</td>
    <td valign="top">CureVac</td>
    <td valign="top">Phase 1 planned in June or July</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Undisclosed SARS-CoV-2-derived synthetic peptide conjugated to the key moiety of the MHC IIâ€“associated invariant chain</td>
    <td valign="top">Generex Biotechnology</td>
    <td valign="top">Human trials planned in June</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Modified vaccinia Ankara VLP vaccine based upon Wuhan strain of SARS-CoV-2</td>
    <td valign="top">GeoVax</td>
    <td valign="top">Candidates in animal studies</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Electroporated linear DNA vaccine based on S protein and selected epitopes</td>
    <td valign="top">LineaRx</td>
    <td valign="top">Four candidates for testing by the beginning of May or June</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Undisclosed recombinant SARS-CoV-2 protein VLP produced in tobacco</td>
    <td valign="top">Medicago</td>
    <td valign="top">preclinical testing ongoing with clinical trials to begin summer 2020</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Recombinant subunit vaccine of SARS-CoV-2 S protein locked in prefusion conformation by polypeptide moiety (molecular clamp)</td>
    <td valign="top">University of Queensland</td>
    <td valign="top">Preclinical as of mid-March</td>
   </tr>
   <tr>
    <td valign="top">/</td>
    <td valign="top">Oral recombinant adenovirus 5 vector vaccine of undisclosed SARS-CoV-2 proteins for mucosal immune response</td>
    <td valign="top">Vaxart</td>
    <td valign="top">Preclinical as of mid-March</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>aAPC, artificial antigen-presenting cell; MHC, major histocompatibility complex class; VLP, virus-like particle; DC, dendritic cell.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
